Access
To read this story in full you will need to login or make a payment (see right).
Brief Communication
Nature Medicine 10, 145 - 147 (2004)
Published online: 25 January 2004 | doi:10.1038/nm988
There is a Corrigendum (June 2004) associated with this Brief Communication.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G Willett1, Yves Boucher1,10, Emmanuelle di Tomaso1,10, Dan G Duda1,10, Lance L Munn1,10, Ricky T Tong1,10, Daniel C Chung2, Dushyant V Sahani3, Sanjeeva P Kalva3, Sergey V Kozin1, Mari Mino4, Kenneth S Cohen5, David T Scadden5, Alan C Hartford1, Alan J Fischman6, Jeffrey W Clark7, David P Ryan7, Andrew X Zhu7, Lawrence S Blaszkowsky7, Helen X Chen9, Paul C Shellito8, Gregory Y Lauwers4 & Rakesh K Jain1
Abstract
The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Targeted therapies Goldie?Coldman and bevacizumab beyond disease progressionNature Reviews Clinical Oncology News and Views (01 Jun 2009)
RESEARCH
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3BOncogene Original Article
See all 16 matches for Research